Skip to main content
Erschienen in: Heart and Vessels 9/2017

04.04.2017 | Original Article

Cardiac hyaluronan may be associated with the persistence of atrial fibrillation

verfasst von: Ayako Okada, Yuichiro Kashima, Takeshi Tomita, Takahiro Takeuchi, Yasutaka Oguchi, Koji Yoshie, Wataru Shoin, Morio Shoda, Kenichi Nitta, Koichiro Kuwahara, Hiroshi Imamura

Erschienen in: Heart and Vessels | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Hyaluronan (HA), a primary component of the extracellular matrix, is associated with several cardiovascular diseases. However, its precise cardiac origin and role in atrial fibrillation (AF) remain unclear. We investigated chamber-specific HA levels in patients with paroxysmal AF (PAF) or persistent AF (PSAF). The levels of HA, a diacron-reactive oxygen metabolite (dROM) as a marker for oxidative stress, at different cardiac sites, and peripheral brain natriuretic peptide (BNP) levels were measured in patients with PAF (n = 50) or PSAF (n = 35). HA levels in the coronary sinus (CS-HA) were significantly higher than those other sites, in both PAF and PSAF patients, and CS-HA levels were significantly higher in PSAF patients than in PAF patients [37.1 (interquartile range, 31.2–48.3) vs. 30.6 (23.7–40.2) pg/mL, P < 0.01]. CS-HA levels were correlated with CS-dROM levels and peripheral BNP levels in PSAF patients (r = 0.417, P = 0.03 and r = 0.579, P < 0.001, respectively), but not in PAF patients (r = −0.115, P = 0.421 and r = 0.048, P = 0.740, respectively). CS-HA levels were elevated in both PAF and PSAF patients and were correlated with cardiac oxidative stress and BNP levels in PSAF patients. Cardiac HA may be associated with the persistence of AF.
Literatur
1.
Zurück zum Zitat Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society (2006) American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114:e257–354 Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society (2006) American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114:e257–354
2.
Zurück zum Zitat Burstein B, Nattel S (2008) Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 51:802–809CrossRefPubMed Burstein B, Nattel S (2008) Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 51:802–809CrossRefPubMed
3.
Zurück zum Zitat Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J (2002) Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 54:361–379CrossRefPubMed Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J (2002) Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 54:361–379CrossRefPubMed
4.
Zurück zum Zitat Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A, Odim J, Laks H, Sen L (2004) Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 109:363–368CrossRefPubMed Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A, Odim J, Laks H, Sen L (2004) Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 109:363–368CrossRefPubMed
5.
Zurück zum Zitat Ling LH, Kistler PM, Ellims AH, Iles LM, Lee G, Hughes GL, Kalman JM, Kaye DM, Taylor AJ (2012) Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and systolic dysfunction. J Am Coll Cardiol 60:2402–2408CrossRef Ling LH, Kistler PM, Ellims AH, Iles LM, Lee G, Hughes GL, Kalman JM, Kaye DM, Taylor AJ (2012) Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and systolic dysfunction. J Am Coll Cardiol 60:2402–2408CrossRef
6.
Zurück zum Zitat Kohl P, Noble D (1996) Mechanosensitive connective tissue: potential influence on heart rhythm. Cardiovasc Res 32:62–68CrossRefPubMed Kohl P, Noble D (1996) Mechanosensitive connective tissue: potential influence on heart rhythm. Cardiovasc Res 32:62–68CrossRefPubMed
7.
Zurück zum Zitat Yue L, Xie J, Nattel S (2011) Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc Res 89:744–753CrossRefPubMed Yue L, Xie J, Nattel S (2011) Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc Res 89:744–753CrossRefPubMed
8.
Zurück zum Zitat Rohr S (2012) Arrhythmogenic implications of fibroblast-myocyte interactions. Circ Arrhythm Electrophysiol 5:442–452CrossRefPubMed Rohr S (2012) Arrhythmogenic implications of fibroblast-myocyte interactions. Circ Arrhythm Electrophysiol 5:442–452CrossRefPubMed
9.
Zurück zum Zitat Laurent TC, Fraser JR (1992) Hyaluronan. FASEB J 6:2397–2404PubMed Laurent TC, Fraser JR (1992) Hyaluronan. FASEB J 6:2397–2404PubMed
10.
Zurück zum Zitat Manabe I, Shindo T, Nagai R (2002) Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 91:1103–1113CrossRefPubMed Manabe I, Shindo T, Nagai R (2002) Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 91:1103–1113CrossRefPubMed
11.
12.
Zurück zum Zitat Swynghedauw B (1999) Molecular mechanisms of myocardial remodeling. Physiol Rev 79:215–262PubMed Swynghedauw B (1999) Molecular mechanisms of myocardial remodeling. Physiol Rev 79:215–262PubMed
13.
Zurück zum Zitat Weber KT, Sun Y, Tyagi SC, Cleutjens JP (1994) Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 26:279–292CrossRef Weber KT, Sun Y, Tyagi SC, Cleutjens JP (1994) Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 26:279–292CrossRef
14.
Zurück zum Zitat Knudson CB, Knudson W (1993) Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J 7:1233–1241 Knudson CB, Knudson W (1993) Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J 7:1233–1241
15.
Zurück zum Zitat Toole BP, Wight TN, Tammi MI (2002) Hyaluronan-cell interactions in cancer and vascular disease. J Biol Chem 277:4593–4596CrossRef Toole BP, Wight TN, Tammi MI (2002) Hyaluronan-cell interactions in cancer and vascular disease. J Biol Chem 277:4593–4596CrossRef
16.
Zurück zum Zitat Lévesque H, Girard N, Maingonnat C, Delpech A, Chauzy C, Tayot J, Courtois H, Delpech B (1994) Localization and solubilization of hyaluronan and of the hyaluronan-binding protein hyaluronectin in human normal and arteriosclerotic arterial walls. Atherosclerosis 105:51–62CrossRefPubMed Lévesque H, Girard N, Maingonnat C, Delpech A, Chauzy C, Tayot J, Courtois H, Delpech B (1994) Localization and solubilization of hyaluronan and of the hyaluronan-binding protein hyaluronectin in human normal and arteriosclerotic arterial walls. Atherosclerosis 105:51–62CrossRefPubMed
17.
Zurück zum Zitat Farb A, Kolodgie FD, Hwang JY, Burke AP, Tefera K, Weber DK, Wight TN, Virmani R (2004) Extracellular matrix changes in stented human coronary arteries. Circulation 110:940–947CrossRefPubMed Farb A, Kolodgie FD, Hwang JY, Burke AP, Tefera K, Weber DK, Wight TN, Virmani R (2004) Extracellular matrix changes in stented human coronary arteries. Circulation 110:940–947CrossRefPubMed
18.
Zurück zum Zitat Kashima Y, Takahashi M, Shiba Y, Itano N, Izawa A, Koyama J, Nakayama J, Taniguchi S, Kimata K, Ikeda U (2013) Crucial role of hyaluronan in neointimal formation after vascular injury. PLoS One 8:e58760CrossRefPubMedCentral Kashima Y, Takahashi M, Shiba Y, Itano N, Izawa A, Koyama J, Nakayama J, Taniguchi S, Kimata K, Ikeda U (2013) Crucial role of hyaluronan in neointimal formation after vascular injury. PLoS One 8:e58760CrossRefPubMedCentral
19.
Zurück zum Zitat Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, Kottkamp H, Dhein S (2004) Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 90:400–405CrossRefPubMedPubMedCentral Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, Kottkamp H, Dhein S (2004) Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 90:400–405CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, Bauer JA (2001) Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104:174–180CrossRefPubMed Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, Bauer JA (2001) Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104:174–180CrossRefPubMed
21.
Zurück zum Zitat Kim YM, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B (2008) Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 51:68–74CrossRefPubMed Kim YM, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B (2008) Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 51:68–74CrossRefPubMed
22.
Zurück zum Zitat Iwasaki YK, Nishida K, Kato T, Nattel S (2011) Atrial fibrillation pathophysiology: implications for management. Circulation 124:2264–2274CrossRef Iwasaki YK, Nishida K, Kato T, Nattel S (2011) Atrial fibrillation pathophysiology: implications for management. Circulation 124:2264–2274CrossRef
23.
Zurück zum Zitat Okada A, Kashima Y, Tomita T, Takeuchi T, Aizawa K, Takahashi M, Ikeda U (2016) Characterization of cardiac oxidative stress levels in patients with atrial fibrillation. Heart Vessels 31:80–87CrossRefPubMed Okada A, Kashima Y, Tomita T, Takeuchi T, Aizawa K, Takahashi M, Ikeda U (2016) Characterization of cardiac oxidative stress levels in patients with atrial fibrillation. Heart Vessels 31:80–87CrossRefPubMed
24.
Zurück zum Zitat Silvet H, Young-Xu Y, Walleigh D, Ravid S (2003) Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 92:1124–1127CrossRefPubMed Silvet H, Young-Xu Y, Walleigh D, Ravid S (2003) Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 92:1124–1127CrossRefPubMed
25.
Zurück zum Zitat Gould PA, Gula LJ, Bhayana V, Subbiah RN, Bentley C, Yee R, Klein GJ, Krahn AD, Skanes AC (2010) Characterization of cardiac brain natriuretic peptide release in patients with paroxysmal atrial fibrillation undergoing left atrial ablation. Circ Arrhythm Electrophysiol 3:18–23CrossRefPubMed Gould PA, Gula LJ, Bhayana V, Subbiah RN, Bentley C, Yee R, Klein GJ, Krahn AD, Skanes AC (2010) Characterization of cardiac brain natriuretic peptide release in patients with paroxysmal atrial fibrillation undergoing left atrial ablation. Circ Arrhythm Electrophysiol 3:18–23CrossRefPubMed
26.
Zurück zum Zitat Villari B, Campbell SE, Hess OM, Mall G, Vassalli G, Weber KT, Krayenbuehl HP (1993) Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. J Am Coll Cardiol 22:1477–1484CrossRef Villari B, Campbell SE, Hess OM, Mall G, Vassalli G, Weber KT, Krayenbuehl HP (1993) Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. J Am Coll Cardiol 22:1477–1484CrossRef
27.
Zurück zum Zitat Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR (1991) Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol 261:H308–H318PubMed Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR (1991) Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol 261:H308–H318PubMed
28.
Zurück zum Zitat John BT, Tamarappoo BK, Titus JL, Edwards WD, Shen WK, Chugh SS (2004) Global remodeling of the ventricular interstitium in idiopathic myocardial fibrosis and sudden cardiac death. Heart Rhythm 1:141–149CrossRefPubMed John BT, Tamarappoo BK, Titus JL, Edwards WD, Shen WK, Chugh SS (2004) Global remodeling of the ventricular interstitium in idiopathic myocardial fibrosis and sudden cardiac death. Heart Rhythm 1:141–149CrossRefPubMed
29.
Zurück zum Zitat Ten Tusscher KH, Panfilov AV (2007) Influence of diffuse fibrosis on wave propagation in human ventricular tissue. Europace 9(Suppl 6):vi38–45CrossRefPubMed Ten Tusscher KH, Panfilov AV (2007) Influence of diffuse fibrosis on wave propagation in human ventricular tissue. Europace 9(Suppl 6):vi38–45CrossRefPubMed
30.
Zurück zum Zitat Fukui M, Goda A, Komamura K, Nakabo A, Masaki M, Yoshida C, Hirotani S, Lee-Kawabata M, Tsujino T, Mano T, Masuyama T (2016) Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failure. Heart Vessels 31:173–182CrossRefPubMed Fukui M, Goda A, Komamura K, Nakabo A, Masaki M, Yoshida C, Hirotani S, Lee-Kawabata M, Tsujino T, Mano T, Masuyama T (2016) Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failure. Heart Vessels 31:173–182CrossRefPubMed
32.
Zurück zum Zitat Volpi N, Schiller J, Stern R, Soltés L (2009) Role, metabolism, chemical modifications and applications of hyaluronan. Curr Med Chem 16:1718–1745CrossRef Volpi N, Schiller J, Stern R, Soltés L (2009) Role, metabolism, chemical modifications and applications of hyaluronan. Curr Med Chem 16:1718–1745CrossRef
33.
Zurück zum Zitat Jiang D, Liang J, Noble PW (2007) Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 23:435–461CrossRef Jiang D, Liang J, Noble PW (2007) Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 23:435–461CrossRef
34.
Zurück zum Zitat Issac TT, Dokainish H, Lakkis NM (2007) Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 50:2021–2028CrossRefPubMed Issac TT, Dokainish H, Lakkis NM (2007) Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 50:2021–2028CrossRefPubMed
Metadaten
Titel
Cardiac hyaluronan may be associated with the persistence of atrial fibrillation
verfasst von
Ayako Okada
Yuichiro Kashima
Takeshi Tomita
Takahiro Takeuchi
Yasutaka Oguchi
Koji Yoshie
Wataru Shoin
Morio Shoda
Kenichi Nitta
Koichiro Kuwahara
Hiroshi Imamura
Publikationsdatum
04.04.2017
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 9/2017
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-017-0972-9

Weitere Artikel der Ausgabe 9/2017

Heart and Vessels 9/2017 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.